Skip to main content
Top
Published in: Endocrine 2/2022

01-05-2022 | Breast Cancer | Original Article

Age-related risk for second breast cancer and gynecological malignant neoplasms after differentiated thyroid cancer

Authors: Xianlan Zhao, Guangrong Yang, Weina Zhang, Qiang Dong, Qiao Yang

Published in: Endocrine | Issue 2/2022

Login to get access

Abstract

Purpose

In this study, we aimed to investigate the age-related risk of second breast cancer (SBC) and second gynecological malignant neoplasms (SGMNs) in female differentiated thyroid cancer (DTC) survivors by utilizing the Surveillance, Epidemiology, and End Results (SEER) database.

Methods

A total number of 55,622 female DTC patients were identified between 1975 and 2016, including 2168 patients who developed SBC and SGMNs. The Fine and Gray model was used to calculate the cumulative incidence and sub-distribution hazards ratios (SHR). Poisson regression analysis was employed to calculate the relative risk (RR) and standardized incidence ratio (SIR). Kaplan–Meier survival and log-rank test analyses were also performed.

Results

The overall 40-year cumulative incidence of SBC and SGMNs was 18.9%. Their incidence in the adolescent and young adults (AYA) group increased slowly in the first 30 years, but then was rapidly elevated in the last decade. It increased gradually in the middle-aged adults group and in the first 25 years in the older adults group, but it scarcely increased thereafter. Both the middle-aged adults (adjusted SHR, 2.09; RR, 1.76) and the older adults (adjusted SHR, 1.32; RR, 1.58) groups had higher risks of developing combined SBC and SGMNs than the AYA group. The risks increased mainly in the early latency period. The three groups also had higher SIRs than the US general population. Besides, the best survival after SBC and SGMNs was observed in the AYA group.

Conclusions

Age was an independent risk factor for SBC and SGMNs incidences among female DTC survivors.
Appendix
Available only for authorised users
Literature
1.
go back to reference S. Vaccarella, S. Franceschi, F. Bray, C.P. Wild, M. Plummer, L. Dal Maso, Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N. Engl. J. Med 375, 614–617 (2016)CrossRef S. Vaccarella, S. Franceschi, F. Bray, C.P. Wild, M. Plummer, L. Dal Maso, Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N. Engl. J. Med 375, 614–617 (2016)CrossRef
2.
go back to reference M. Li, L. Dal Maso, S. Vaccarella, Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8, 468–470 (2020)CrossRef M. Li, L. Dal Maso, S. Vaccarella, Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8, 468–470 (2020)CrossRef
3.
go back to reference L.B. Vergamini, A.L. Frazier, F.L. Abrantes, K.B. Ribeiro, C. Rodriguez-Galindo, Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J. Pediatr. 164, 1481–1485 (2014)CrossRef L.B. Vergamini, A.L. Frazier, F.L. Abrantes, K.B. Ribeiro, C. Rodriguez-Galindo, Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J. Pediatr. 164, 1481–1485 (2014)CrossRef
4.
go back to reference M. Russo, P. Malandrino, M. Moleti, A. D’Angelo, M. Tavarelli, G. Sapuppo et al. Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment. Anticancer Res 37, 1515–1522 (2017)CrossRef M. Russo, P. Malandrino, M. Moleti, A. D’Angelo, M. Tavarelli, G. Sapuppo et al. Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment. Anticancer Res 37, 1515–1522 (2017)CrossRef
5.
go back to reference C.A. Lebbink, M.F.M. van den Broek, A.B.G. Kwast, J.P.M. Derikx, M.P. Dierselhuis, S. Kruijff et al. Opposite incidence trends for differentiated and medullary thyroid cancer in young dutch patients over a 30-year time span. Cancers 13, 5104 (2021)CrossRef C.A. Lebbink, M.F.M. van den Broek, A.B.G. Kwast, J.P.M. Derikx, M.P. Dierselhuis, S. Kruijff et al. Opposite incidence trends for differentiated and medullary thyroid cancer in young dutch patients over a 30-year time span. Cancers 13, 5104 (2021)CrossRef
6.
go back to reference S. Vaccarella, J. Lortet-Tieulent, M. Colombet, L. Davies, C.A. Stiller, J. Schuz et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. Lancet Diabetes Endocrinol. 9, 144–152 (2021)CrossRef S. Vaccarella, J. Lortet-Tieulent, M. Colombet, L. Davies, C.A. Stiller, J. Schuz et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. Lancet Diabetes Endocrinol. 9, 144–152 (2021)CrossRef
7.
go back to reference H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 317, 1338–1348 (2017)CrossRef H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA 317, 1338–1348 (2017)CrossRef
8.
go back to reference L. Rahib, B.D. Smith, R. Aizenberg, A.B. Rosenzweig, J.M. Fleshman, L.M. Matrisian, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014)CrossRef L. Rahib, B.D. Smith, R. Aizenberg, A.B. Rosenzweig, J.M. Fleshman, L.M. Matrisian, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014)CrossRef
9.
go back to reference H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021)CrossRef H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021)CrossRef
10.
go back to reference R. Yao, C.G. Chiu, S.S. Strugnell, S. Gill, S.M. Wiseman, Gender differences in thyroid cancer: a critical review. Expert Rev. Endocrinol. Metab. 6, 215–243 (2011)CrossRef R. Yao, C.G. Chiu, S.S. Strugnell, S. Gill, S.M. Wiseman, Gender differences in thyroid cancer: a critical review. Expert Rev. Endocrinol. Metab. 6, 215–243 (2011)CrossRef
11.
go back to reference S.J. Schonfeld, G. Neta, E.M. Sturgis, R.M. Pfeiffer, A.A. Hutchinson, L. Xu et al. Common genetic variants in sex hormone pathway genes and papillary thyroid cancer risk. Thyroid 22, 151–156 (2012)CrossRef S.J. Schonfeld, G. Neta, E.M. Sturgis, R.M. Pfeiffer, A.A. Hutchinson, L. Xu et al. Common genetic variants in sex hormone pathway genes and papillary thyroid cancer risk. Thyroid 22, 151–156 (2012)CrossRef
12.
go back to reference J. Zidan, D. Karen, M. Stein, E. Rosenblatt, W. Basher, A. Kuten, Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 97, 1181–1185 (2003)CrossRef J. Zidan, D. Karen, M. Stein, E. Rosenblatt, W. Basher, A. Kuten, Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 97, 1181–1185 (2003)CrossRef
13.
go back to reference G.H. Jossart, O.H. Clark, Well-differentiated thyroid cancer. Curr. Probl. Surg. 31, 933–1012 (1994)CrossRef G.H. Jossart, O.H. Clark, Well-differentiated thyroid cancer. Curr. Probl. Surg. 31, 933–1012 (1994)CrossRef
14.
go back to reference L. Yu, H. Hong, J. Han, S.X. Leng, H. Zhang, X. Yan, Comparison of survival and risk factors of differentiated thyroid cancer in the geriatric population. Front Oncol. 10, 42 (2020)CrossRef L. Yu, H. Hong, J. Han, S.X. Leng, H. Zhang, X. Yan, Comparison of survival and risk factors of differentiated thyroid cancer in the geriatric population. Front Oncol. 10, 42 (2020)CrossRef
15.
go back to reference E. Izkhakov, M. Barchana, I. Liphshitz, B.G. Silverman, N. Stern, L. Keinan-Boker, Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel. Thyroid 27, 793–801 (2017)CrossRef E. Izkhakov, M. Barchana, I. Liphshitz, B.G. Silverman, N. Stern, L. Keinan-Boker, Trends of Second Primary Malignancy in Patients with Thyroid Cancer: A Population-Based Cohort Study in Israel. Thyroid 27, 793–801 (2017)CrossRef
16.
go back to reference T.C. Sandeep, M.W. Strachan, R.M. Reynolds, D.H. Brewster, G. Scelo, E. Pukkala et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab. 91, 1819–1825 (2006)CrossRef T.C. Sandeep, M.W. Strachan, R.M. Reynolds, D.H. Brewster, G. Scelo, E. Pukkala et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J. Clin. Endocrinol. Metab. 91, 1819–1825 (2006)CrossRef
17.
go back to reference M. Karakose, I. Cordan, M. Can, M. Kocabas, M. Kulaksizoglu, F. Karakurt, Incidence of second primary malignancies in patients with thyroid cancer in the Turkish population. Turk. J. Med Sci. 49, 1529–1533 (2019)CrossRef M. Karakose, I. Cordan, M. Can, M. Kocabas, M. Kulaksizoglu, F. Karakurt, Incidence of second primary malignancies in patients with thyroid cancer in the Turkish population. Turk. J. Med Sci. 49, 1529–1533 (2019)CrossRef
18.
go back to reference H. Sung, N. Hyun, C.R. Leach, K.R. Yabroff, A. Jemal, Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States. JAMA 324, 2521–2535 (2020)CrossRef H. Sung, N. Hyun, C.R. Leach, K.R. Yabroff, A. Jemal, Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States. JAMA 324, 2521–2535 (2020)CrossRef
19.
go back to reference S.M. Nielsen, M.G. White, S. Hong, B. Aschebrook-Kilfoy, E.L. Kaplan, P. Angelos et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol. Biomark. Prev. 25, 231–238 (2016)CrossRef S.M. Nielsen, M.G. White, S. Hong, B. Aschebrook-Kilfoy, E.L. Kaplan, P. Angelos et al. The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis. Cancer Epidemiol. Biomark. Prev. 25, 231–238 (2016)CrossRef
20.
go back to reference S. Shah, L. Boucai, Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. J. Clin. Endocrinol. Metab. 103, 689–697 (2018)CrossRef S. Shah, L. Boucai, Effect of age on response to therapy and mortality in patients with thyroid cancer at high risk of recurrence. J. Clin. Endocrinol. Metab. 103, 689–697 (2018)CrossRef
21.
go back to reference J. Tang, D. Kong, Q. Cui, K. Wang, D. Zhang, X. Liao et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco. Targets Ther. 11, 3551–3560 (2018)CrossRef J. Tang, D. Kong, Q. Cui, K. Wang, D. Zhang, X. Liao et al. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. Onco. Targets Ther. 11, 3551–3560 (2018)CrossRef
22.
go back to reference G. Liu, Q. Liu, S.R. Sun, Nomograms for estimating survival in patients with papillary thyroid cancer after surgery. Cancer Manag Res 11, 3535–3544 (2019)CrossRef G. Liu, Q. Liu, S.R. Sun, Nomograms for estimating survival in patients with papillary thyroid cancer after surgery. Cancer Manag Res 11, 3535–3544 (2019)CrossRef
23.
go back to reference G. Zirilli, L. Cannavo, F. Vermiglio, M.A. Violi, F. Luca, M. Wasniewska, Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. Ital. J. Pediatr. 44, 13 (2018)CrossRef G. Zirilli, L. Cannavo, F. Vermiglio, M.A. Violi, F. Luca, M. Wasniewska, Differentiated thyroid carcinoma presentation may be more aggressive in children and adolescents than in young adults. Ital. J. Pediatr. 44, 13 (2018)CrossRef
24.
go back to reference Y.Y. Cho, J. Lim, C.M. Oh, J. Ryu, K.W. Jung, J.H. Chung et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 121, 259–268 (2015)CrossRef Y.Y. Cho, J. Lim, C.M. Oh, J. Ryu, K.W. Jung, J.H. Chung et al. Elevated risks of subsequent primary malignancies in patients with thyroid cancer: a nationwide, population-based study in Korea. Cancer 121, 259–268 (2015)CrossRef
25.
go back to reference A.Y. Chen, L. Levy, H. Goepfert, B.W. Brown, M.R. Spitz, R. Vassilopoulou-Sellin, The development of breast carcinoma in women with thyroid carcinoma. Cancer 92, 225–231 (2001)CrossRef A.Y. Chen, L. Levy, H. Goepfert, B.W. Brown, M.R. Spitz, R. Vassilopoulou-Sellin, The development of breast carcinoma in women with thyroid carcinoma. Cancer 92, 225–231 (2001)CrossRef
26.
go back to reference E. Adjadj, C. Rubino, A. Shamsaldim, M.G. Le, M. Schlumberger, F. de Vathaire, The risk of multiple primary breast and thyroid carcinomas. Cancer 98, 1309–1317 (2003)CrossRef E. Adjadj, C. Rubino, A. Shamsaldim, M.G. Le, M. Schlumberger, F. de Vathaire, The risk of multiple primary breast and thyroid carcinomas. Cancer 98, 1309–1317 (2003)CrossRef
27.
go back to reference C.M. Ronckers, P. McCarron, E. Ron, Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J. Cancer 117, 281–288 (2005)CrossRef C.M. Ronckers, P. McCarron, E. Ron, Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J. Cancer 117, 281–288 (2005)CrossRef
28.
go back to reference P. Tralongo, A. Surbone, D. Serraino, L. Dal Maso, Major patterns of cancer cure: Clinical implications. Eur. J. Cancer Care (Engl.) 28, e13139 (2019)CrossRef P. Tralongo, A. Surbone, D. Serraino, L. Dal Maso, Major patterns of cancer cure: Clinical implications. Eur. J. Cancer Care (Engl.) 28, e13139 (2019)CrossRef
29.
go back to reference C.H. Lu, K.D. Lee, P.T. Chen, C.C. Chen, F.C. Kuan, C.E. Huang et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur. J. Endocrinol. 169, 577–585 (2013)CrossRef C.H. Lu, K.D. Lee, P.T. Chen, C.C. Chen, F.C. Kuan, C.E. Huang et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur. J. Endocrinol. 169, 577–585 (2013)CrossRef
30.
go back to reference B.H. Lang, C.Y. Lo, I.O. Wong, B.J. Cowling, Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma. Surgery 148, 1191–1196 (2010).CrossRef B.H. Lang, C.Y. Lo, I.O. Wong, B.J. Cowling, Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma. Surgery 148, 1191–1196 (2010).CrossRef
31.
go back to reference R.T. Frankle, Nutrition education in the medical school curriculum: a proposal for action: a curriculum design. Am. J. Clin. Nutr. 29, 105–109 (1976)CrossRef R.T. Frankle, Nutrition education in the medical school curriculum: a proposal for action: a curriculum design. Am. J. Clin. Nutr. 29, 105–109 (1976)CrossRef
32.
go back to reference B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016)CrossRef
33.
go back to reference A.M. Sawka, L. Thabane, L. Parlea, I. Ibrahim-Zada, R.W. Tsang, J.D. Brierley et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19, 451–457 (2009)CrossRef A.M. Sawka, L. Thabane, L. Parlea, I. Ibrahim-Zada, R.W. Tsang, J.D. Brierley et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19, 451–457 (2009)CrossRef
34.
go back to reference A.P. Brown, J. Chen, Y.J. Hitchcock, A. Szabo, D.C. Shrieve, J.D. Tward, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 93, 504–515 (2008)CrossRef A.P. Brown, J. Chen, Y.J. Hitchcock, A. Szabo, D.C. Shrieve, J.D. Tward, The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 93, 504–515 (2008)CrossRef
35.
go back to reference M. Silva-Vieira, S. Carrilho Vaz, S. Esteves, T.C. Ferreira, E. Limbert, L. Salgado et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? Thyroid 27, 1068–1076 (2017)CrossRef M. Silva-Vieira, S. Carrilho Vaz, S. Esteves, T.C. Ferreira, E. Limbert, L. Salgado et al. Second Primary Cancer in Patients with Differentiated Thyroid Cancer: Does Radioiodine Play a Role? Thyroid 27, 1068–1076 (2017)CrossRef
36.
go back to reference V. Drozd, R. Schneider, T. Platonova, G. Panasiuk, T. Leonova, N. Oculevich et al. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients. Front Endocrinol. 11, 567385 (2020)CrossRef V. Drozd, R. Schneider, T. Platonova, G. Panasiuk, T. Leonova, N. Oculevich et al. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients. Front Endocrinol. 11, 567385 (2020)CrossRef
37.
go back to reference C. Reiners, R. Schneider, T. Platonova, M. Fridman, U. Malzahn, U. Mader et al. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. Front Endocrinol. 11, 381 (2020)CrossRef C. Reiners, R. Schneider, T. Platonova, M. Fridman, U. Malzahn, U. Mader et al. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. Front Endocrinol. 11, 381 (2020)CrossRef
Metadata
Title
Age-related risk for second breast cancer and gynecological malignant neoplasms after differentiated thyroid cancer
Authors
Xianlan Zhao
Guangrong Yang
Weina Zhang
Qiang Dong
Qiao Yang
Publication date
01-05-2022
Publisher
Springer US
Published in
Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-022-02999-9

Other articles of this Issue 2/2022

Endocrine 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine